Mucolipidosis type IV (MLIV) is a rare autosomal recessive neurodegenerative disease caused by mutations of MCOLN1, which codes of mucolipin-1 a putative cation channel located in lysosomes. This research proposal aims to study the natural history of neurological and retinal manifestations of MLIV It also aims to increase awareness and improve diagnosis of MLIV among patients with cerebral palsy and those with retinal dystrophy of unknown cause. Over the past decade we have been studying prospectively various clinical and genetic aspects of MLIV in the only study of its kind. We hypothesize that MLIV is a combination of mostly developmental abnormality in the CMS and a degenerative retinal process. In this application we propose to 1) recruit known and newly diagnosed patients with MLIV and systematically study the neurological and retinal function over time. 2) Contact practicing physicians that take care of cerebral palsy patients and those with retinal dystrophy to increased awareness and improve diagnosis of MLIV. Based on our experience, we believe that many MLIV patients go undiagnosed. This project will help characterize and quantify the clinical abnormalities of MLIV and thus help define a patient population and outcome measures for future clinical trials.

Public Health Relevance

Known and newly diagnosed patients with MLIV will be studied over time for neurological and retinal function. Practicing physicians that take care of cerebral palsy patients and those with retinal dystrophy will be contacted to increase awareness and improve diagnosis of MLIV as many may go undiagnosed. This study will help characterize and quantify the clinical abnormalities of MLIV and provide outcome measures for future clinical trials.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54NS065768-03
Application #
8325941
Study Section
Special Emphasis Panel (ZRG1)
Project Start
Project End
Budget Start
2011-09-01
Budget End
2012-08-31
Support Year
3
Fiscal Year
2011
Total Cost
$45,387
Indirect Cost
Name
University of Minnesota Twin Cities
Department
Type
DUNS #
555917996
City
Minneapolis
State
MN
Country
United States
Zip Code
55455
Ou, Li; Przybilla, Michael J; Whitley, Chester B (2018) Metabolomics profiling reveals profound metabolic impairments in mice and patients with Sandhoff disease. Mol Genet Metab :
McIntosh, Paul T; Hobson-Webb, Lisa D; Kazi, Zoheb B et al. (2018) Neuroimaging findings in infantile Pompe patients treated with enzyme replacement therapy. Mol Genet Metab 123:85-91
Nestrasil, Igor; Ahmed, Alia; Utz, Josephine M et al. (2018) Distinct progression patterns of brain disease in infantile and juvenile gangliosidoses: Volumetric quantitative MRI study. Mol Genet Metab 123:97-104
Ou, Li; Przybilla, Michael J; Koniar, Brenda et al. (2018) RTB lectin-mediated delivery of lysosomal ?-l-iduronidase mitigates disease manifestations systemically including the central nervous system. Mol Genet Metab 123:105-111
Desai, Ankit K; Walters, Crista K; Cope, Heidi L et al. (2018) Enzyme replacement therapy with alglucosidase alfa in Pompe disease: Clinical experience with rate escalation. Mol Genet Metab 123:92-96
Sindelar, Miriam; Dyke, Jonathan P; Deeb, Ruba S et al. (2018) Untargeted Metabolite Profiling of Cerebrospinal Fluid Uncovers Biomarkers for Severity of Late Infantile Neuronal Ceroid Lipofuscinosis (CLN2, Batten Disease). Sci Rep 8:15229
Shapiro, Elsa G; Whitley, Chester B; Eisengart, Julie B (2018) Beneath the floor: re-analysis of neurodevelopmental outcomes in untreated Hurler syndrome. Orphanet J Rare Dis 13:76
Ou, L; Przybilla, M J; Whitley, C B (2018) SAAMP 2.0: An algorithm to predict genotype-phenotype correlation of lysosomal storage diseases. Clin Genet 93:1008-1014
Eisengart, Julie B; Rudser, Kyle D; Xue, Yong et al. (2018) Long-term outcomes of systemic therapies for Hurler syndrome: an international multicenter comparison. Genet Med 20:1423-1429
Kazi, Zoheb B; Desai, Ankit K; Troxler, R Bradley et al. (2018) An immune tolerance approach using transient low-dose methotrexate in the ERT-naïve setting of patients treated with a therapeutic protein: experience in infantile-onset Pompe disease. Genet Med :

Showing the most recent 10 out of 118 publications